maxcyte.com - יחס שווי כולל של החברה להכנסות MXCT

MaxCyte Inc. (MXCT) - לוגו תאגידי

MaxCyte, Inc. (MXCT) combines tight software integration into B2B cycles with the sale of electroporation systems to pharma behemoths. The EV/Sales multiple helps balance this technological client dependency with market valuation, while 1299.68 indicates the current level. Licensing payments provide stability, although growth potential depends on new clinical agreements.

מכפיל EV/Sales MaxCyte, Inc (MXCT): לתקופה 23.11.2025 - 19.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור MaxCyte, Inc (MXCT)

- מחיר מניה וקונצנזוס הערכת שווי:
- פרטי שווי השוק של המנפיק:
הערכת שווי פונדמנטלית של החברה:MXCT, maxcyte.com
סחורת הדגל של MaxCyte Inc.

For MaxCyte, Inc. (MXCT), the enterprise value-to-sales multiple reflects the market valuation of the business without the influence of debt load. This metric compares total asset value with annual revenue, excluding debt distortions. Such a mechanism allows for an assessment of the actual scale of operations and the premium for technological leadership. In the case of MaxCyte, Inc. (MXCT), the high valuation is justified by the uniqueness of its patented electroporation and its critical integration into biomanufacturing. The stability of this metric serves as an indicator of the issuer's resilient market position.

ניתוח מתחרים